The impact of donor age on the outcome of adult living donor liver transplantation

Transplantation. 2008 May 15;85(9):1240-5. doi: 10.1097/TP.0b013e31816c7e90.

Abstract

Background: The negative effects of increased donor age on liver transplantation became evident in deceased donor liver transplantation. In living donor liver transplantation (LDLT), the details remain unclear.

Methods: Initially, 137 adult LDLT recipients from August 1996 to May 2005 were divided into two groups (donors <50 years of age: n=99, donors >or= 50 years of age: n=38) for the retrospective study. Then, 24 recipients who received LDLT from June 2005 to July 2006 were divided into two groups: group 1 (donors <50 years of age, n=14) and group 2 (donors >or= 50 years of age, n=10) and enrolled in the prospective study to analyze their clinical course and prognostic factors in the aged graft.

Results: In the retrospective study, the younger donor group had significantly better survival than that of the aged donor group (P=0.015, Log rank test). In the prospective study, the postoperative graft functions showed that the serum total bilirubin levels were significantly lower in group 1 (P<0.02, by ANOVA analysis). The phosphorylated-Signal Transducer and Activator of Transcription3 expression at 4 hr after reperfusion (RT2) in group 2 was significantly lower than that in group 1. At RT2, the expressions were up-regulated in group 1, but were down-regulated in group 2. The serum 8-hydroxydeoxyguanosine value became significantly higher in group 1 two weeks after LDLT.

Conclusions: In the near term, Signal Transducer and Activator of Transcription3 gene induction during cold preservation may be of great use in improving the outcome of aged grafts in LDLT.

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Adolescent
  • Adult
  • Age Factors*
  • Biomarkers / blood
  • Deoxyguanosine / analogs & derivatives
  • Deoxyguanosine / blood
  • Hepatectomy* / mortality
  • Humans
  • Liver*
  • Living Donors*
  • Middle Aged
  • Patient Selection
  • Retrospective Studies
  • STAT1 Transcription Factor / genetics
  • STAT2 Transcription Factor / genetics
  • STAT3 Transcription Factor / genetics
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers
  • STAT1 Transcription Factor
  • STAT2 Transcription Factor
  • STAT3 Transcription Factor
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine